Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Serono (SWX:SEO; SRA) reported second quarter earnings per ADS of $0.17, up 13% over $0.15 in the second quarter of
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury